The Effectiveness of Telemedicine Solutions for the Management of Type 2 Diabetes: A Systematic Review, Meta-Analysis, and Meta-Regression
Open accessThe DOI matches its Crossref record; 295 of the 295 references it cites were found in a registry or an index; 21 of the 39 sources its claims cite were checked for support.
Abstract
Background: Previous systematic reviews have aimed to clarify the effect of telemedicine on diabetes. However, such reviews often have a narrow focus, which calls for a more comprehensive systematic review within the field. Hence, the objective of the present systematic review, meta-analysis, and meta-regression is to evaluate the effectiveness of telemedicine solutions versus any comparator without the use of telemedicine on diabetes-related outcomes among adult patients with type 2 diabetes (T2D). Methods: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We considered telemedicine randomized controlled trials (RCT) including adults (≥18 years) diagnosed with T2D. Change in glycated hemoglobin (HbA1c, %) was the primary outcome. PubMed, EMBASE, and the Cochrane Library Central Register of Controlled Trials (CENTRAL) were searched on October 14, 2020. An overall treatment effect was estimated using a meta-analysis performed on the pool of included studies based on the mean difference (MD). The revised Cochrane risk-of-bias tool was applied and the certainty of evidence was graded using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Results: The final sample of papers included a total of 246, of which 168 had sufficient information to calculate the effect of HbA1c%. The results favored telemedicine, with an MD of −0.415% (95% confidence interval [CI] = −0.482% to −0.348%). The heterogeneity was great (I 2 = 93.05%). A monitoring component gave rise to the higher effects of telemedicine. Conclusions: In conclusion, telemedicine may serve as a valuable supplement to usual care for patients with T2D. The inclusion of a telemonitoring component seems to increase the effect of telemedicine.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found that telemedicine favored non-telemedicine comparators for reducing HbA1c in adults with type 2 diabetes, with a pooled mean difference of −0.415% (95% CI = −0.482% to −0.348%). The certainty of evidence was low, and heterogeneity was high, but a telemonitoring component and higher baseline HbA1c were associated with larger effects.
Key findings
- Among 168 studies with sufficient HbA1c data, telemedicine reduced HbA1c versus comparator: MD = −0.415% (95% CI = −0.482% to −0.348%), with large heterogeneity (I² = 93.05%).
- Meta-regression found greater effects for a monitoring component (difference in MD = −0.195, P = .004), Asian versus North American studies (difference in MD = −0.287, P = .000), hospital versus primary care settings (difference in MD = −0.290, P = .004), and higher baseline HbA1c (text reports difference in MD = −0.086 per %, P = .008; table reports −0.093 per %, P = .007). A coaching component was associated with a lower effect (difference in MD = 0.215, P = .007).
- Risk of bias was high in 45% of studies, moderate in 38%, and low in 17%; GRADE certainty for HbA1c was judged low due to serious risk of bias and inconsistency. The summary of findings table reports 29,671 telemedicine and 27,465 usual-practice patients (N = 57,136).
Methods
- PRISMA-guided systematic review, meta-analysis, and meta-regression (PROSPERO CRD42020123565), including randomized controlled trials of adults ≥18 years with type 2 diabetes, comparing telemedicine with any comparator without telemedicine; primary outcome was change in HbA1c%.
- Searches covered PubMed, EMBASE, Cochrane CENTRAL, and CINAHL, plus citation searches, through October 14, 2020; included studies were peer-reviewed full-text papers in English, Danish, Norwegian, or Swedish.
- Random-effects meta-analysis estimated mean differences; heterogeneity was assessed with I²; univariate meta-regression examined study, patient, and telemedicine characteristics; risk of bias used the revised Cochrane tool, and certainty was graded with GRADE.
Limitations
- The paper states that more baseline data could have been extracted (eg, diabetes years, blood pressure, cholesterol, medication) but missingness would have been high; authors were not contacted to minimize missing HbA1c data because of the large number of papers; relevant studies may have been overlooked; and the search was limited to English and Scandinavian languages.
- Evident from the text: heterogeneity was very high (I² = 93.05%), certainty of evidence was low, 45% of studies had high risk of bias and only 17% low risk, and although publication bias was judged undetected, the Egger test was statistically significant (P < .000) and the funnel plot was somewhat asymmetrical.
- The text also inconsistently reports the final included sample as 246 articles in one place and 243 studies in later analyses, which is an evident reporting limitation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 0 Not valid · 9 Not checked · 48 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In line with our findings, Faruque et al and Wu et al found a larger effect among studies with a higher baseline HbA1c.13,283”
What the sources say
- Supportedcites [13] Faruque LI, Wiebe N, Ehteshami-Afshar A, et al. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. Cmaj. 2017;189:E341-E364. doi: 10.1503/cmaj.150885. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Meta-regression analysis says baseline HbA1c modified telemedicine’s effect on final HbA1c. Table 4 reports a more favorable estimated effect at higher baseline HbA1c, although the association was not statistically significant (−0.06 per 1% increase; 95% CI −0.16 to 0.04; p = 0.3). (LLM, conf=0.85)
- Supportedcites [283] Wu C, Wu Z, Yang L, et al. Evaluation of the clinical outcomes of telehealth for managing diabetes: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2018;97:e12962. doi: 10.1097/MD.0000000000012962. [DOI] [PMC free article] [PubMed] [Google Scholar] source
For the claim attributed to Wu et al., the Results (Diabetic control outcomes; page not provided) report a larger average HbA1c change among telehealth participants with baseline HbA1c ≥9% than among those below 9%. The Discussion describes this as a potentially greater effect for participants with higher baseline HbA1c. This verdict does not assess the separate citation to Faruque et al. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and Jaana et al found significantly reduced HbA1 through telemonitoring. 22”
What the sources say
- Supportedcites [22] Pare G, Janna M, Sicotte C. Systematic review of home telemonitoring for chronic diseases: the evidence base home telemonitoring: a definition. J Am Med Informatics Assoc. 2007;14(3):269-277. [DOI] [PMC free article] [PubMed] [Google Scholar] source
In the 'Telemonitoring Effects' section our copy states that 'diabetes telemonitoring studies have confirmed a decline in hemoglobin A1c and significant blood glucose control as a result of this approach' (refs 52, 53, 56, 59), which is exactly what the citing sentence attributes to Jaana et al (co-author M. Jaana of this Pare/Jaana/Sicotte systematic review). The finding is reported as a synthesis of the included diabetes trials rather than as this paper's own primary data, and the review qualifies the overall positive effects elsewhere (e.g., inconsistent evidence on complications, ref 28, 29), but the HbA1c point itself is stated here. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In terms of telemonitoring, Hanlon et al found improved glycemic control in studies that included telemonitoring with feedback 17”
What the sources say
- Supportedcites [17] Hanlon P, Daines L, Campbell C, McKinstry B, Weller D, Pinnock H. Telehealth interventions to support self-management of long-term conditions: a systematic metareview of diabetes, heart failure, asthma, chronic obstructive pulmonary disease, and cancer. J Med Internet Res. 2017;19(5):e172. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Results section (Impact of Telehealth Interventions on Disease Control and Health Care Utilization; page unavailable) reports HbA1c improvements in several reviews involving blood-glucose telemonitoring. The Discussion (Comparison With Other Literature; page unavailable) says that active monitoring of blood glucose with feedback in type 2 diabetes was often associated with improved outcomes. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As diabetes predominantly needs to be managed outside health care facilities and to a large extent requires self-management, telemedicine holds the potential to provide sufficient self-management support to people with T2D.18,19”
What the sources say
- Partly supportedcites [18] Crico C, Renzi C, Graf N, et al. mHealth and telemedicine apps: in search of a common regulation. Ecancermedicalscience. 2018;12:853. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes remote services that can support self-care management, and the Conclusion calls health apps promising for self-management. The paper does not specifically address people with type 2 diabetes or establish that telemedicine can provide sufficient support for their self-management; it says app efficacy remains difficult to assess. (LLM, conf=0.84)
- Not checked yetcites [19] Mahar JH, Rosencrance GJ, Rasmussen PA. Telemedicine: past, present, and future. Cleve Clin J Med. 2018;85(12):938-942. [DOI] [PubMed] [Google Scholar] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, these previous reviews have often focused on a specific type of telemedicine, a specific outcome, and/or a specific comparator, which calls for a more comprehensive and inclusive systematic review seeking to compare and synthesize findings for treatment outcomes while adjusting for different study characteristics.”
What the sources say
- Supportedcites [15] Baron J, Mcbain H, Newman S, Psych D, Hons M. The impact of mobile monitoring technologies on glycosylated. J Diabetes Sci Technol. 2012;6:1185-1196. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Introduction describes earlier diabetes telehealth reviews that focused only on mobile platforms, and this review itself focuses on mobile telemonitoring and HbA1c. Those examples support the citing sentence’s qualified description of reviews focused on particular technologies and/or outcomes; the call for a more inclusive review is the citing authors’ own conclusion. (LLM, conf=0.84)
- Supportedcites [16] Holtz B, Lauckner C. Diabetes management via mobile phones: a systematic review. Telemed J E Health. 2012;18(3):175-184. [DOI] [PubMed] [Google Scholar] source
The Abstract and Study Selection sections identify this as a systematic review of mobile-phone interventions for diabetes, making it an example of a previous review focused on a specific type of telemedicine. The claim says “and/or,” so the source need not also focus on a specific outcome or comparator. The citing authors’ call for a more comprehensive review is their own conclusion. (LLM, conf=0.90)
- Supportedcites [17] Hanlon P, Daines L, Campbell C, McKinstry B, Weller D, Pinnock H. Telehealth interventions to support self-management of long-term conditions: a systematic metareview of diabetes, heart failure, asthma, chronic obstructive pulmonary disease, and cancer. J Med Internet Res. 2017;19(5):e172. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Results (Diabetes; page not provided) describe reviews restricted to mobile messaging, blood-glucose telemonitoring, telephone interventions, or teleconsultations. They also report reviews assessing HbA1c against usual care. These examples support the claim that previous diabetes reviews often focused on a particular intervention type, outcome, and/or comparator; the call for a more comprehensive review is the citing authors’ own rationale. (LLM, conf=0.88)
- Supportedcites [20] Greenwood DA, Young HM, Quinn CC. Telehealth remote monitoring systematic review. J Diabetes Sci Technol. 2014;8(2):378-389. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Data Sources and Review section limits this systematic review to telehealth remote blood-glucose monitoring in adults with type 2 diabetes and its impact on A1C. The paper is therefore an example of a previous review focused on a specific form of telemedicine and a specific outcome; the claim does not require it to have a specific comparator. (LLM, conf=0.90)
- Not checked yetcites [21] Jaana M, Paré G. Home telemonitoring of patients with diabetes: a systematic assessment of observed effects. J Eval Clin Pract. 2007;13:242-253. doi: 10.1111/j.1365-2753.2006.00686.x. [DOI] [PubMed] [Google Scholar] source
- Supportedcites [22] Pare G, Janna M, Sicotte C. Systematic review of home telemonitoring for chronic diseases: the evidence base home telemonitoring: a definition. J Am Med Informatics Assoc. 2007;14(3):269-277. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Abstract describes this paper as a systematic review that includes diabetes, while the Methodology limits it to home telemonitoring rather than telemedicine generally. It therefore serves as an example of a previous review focused on a specific type of telemedicine; the claim’s “and/or” does not require it also to focus on one outcome or comparator. (LLM, conf=0.87)
- Not checked yetcites [23] Wu L, Forbes A, Griffiths P, Milligan P, While A. Telephone follow-up to improve glycaemic control in patients with type 2 diabetes: systematic review and meta-analysis of controlled trials. Diabet Med. 2010;27(11):1217-1225. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [24] Yun JE, Park JE, Park HY, Lee HY, Park DA. Comparative effectiveness of telemonitoring versus usual care for heart failure: a systematic review and meta-analysis. J Card Fail. 2018;24(1):19-28. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [25] Cassimatis M, Kavanagh DJ. Effects of type 2 diabetes behavioural telehealth interventions on glycaemic control and adherence: a systematic review. J Telemed Telecare. 2012;18(8):447-450. [DOI] [PubMed] [Google Scholar] source
- Could not verifycites [26] Lee SWH, Ooi L, Lai YK. Telemedicine for the management of glycemic control and clinical outcomes of type 1 diabetes mellitus: a systematic review and meta-analysis of randomized controlled studies. Front Pharmacol. 2017;8:330. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Introduction says previous reviews found mixed results and that evidence for type 1 diabetes was scarcer than for type 2. It does not say those reviews often restricted themselves to a particular telemedicine type, outcome, or comparator; searches for those limitations found no such passage in our copy. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
30 more claims · 2 with their cited sources checked
Create a free account to see all 67 claims and to verify the 18 references still open.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The included studies exhibited substantial heterogeneity (I²=94%), a common finding in telemedicine reviews, where heterogeneity typically ranges from 65% to 99% [17,22,86,93].”
From Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression (2026) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The included studies exhibited substantial heterogeneity (I²=94%), a common finding in telemedicine reviews, where heterogeneity typically ranges from 65% to 99% [17,22,86,93].”
From Clinical Improvements From Telemedicine Interventions for Managing Type 2 Diabetes Compared With Usual Care: Systematic Review, Meta-Analysis, and Meta-Regression (2026) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of those, 3 reviews reported telemonitoring combined with tele-education [44] and telemonitoring combined with healthcare professional feedback [45, 48] had greater effects.”
From Effect of virtual care in type 2 diabetes management – a systematic umbrella review of systematic reviews and meta-analysis (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The extracted results for these outcomes were limited and heterogeneous, making it difficult to draw definitive conclusions about the effectiveness of virtual care on these parameters [40, 45].”
From Effect of virtual care in type 2 diabetes management – a systematic umbrella review of systematic reviews and meta-analysis (2025) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“HbA1c% 243 Randomized trials Serious a Serious b Not serious Not serious None 29 671 27 465 − MD 0.415 lower (0.482 lower to 0.348 lower)”
§ Results
“Of the 243 studies, 168 had sufficient information to calculate an MD with standard errors for the effect on HbA1c%”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“studies with higher baseline HbA1c% levels (difference in MD = −0.086 per %, P = .008).”
§ Results
“Baseline HbA1c% (range = 5.70%-11.05%) 165 −0.093 per % (0.035) .007 * 92.80”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“Publication decade Before 2020 4 Reference 92.86 2020s 50 −0.175 (0.287) .542”
§ Results
“Four studies were published before 2000 (2%), 50 in the 2000s (21%), 165 in the 2010s (68%), and 24 (10%) in 2020.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“five in Africa (2%), and five in South America (5%).”
Reported 5 · recomputed 2.03252
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Estimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Research works printed but not linked: 3
- WHO Global Observatory for eHealth. Telemedicine: opportunities and developments in member states. Observatory. 2010;2:96.
- Chiu CJ, Hu YH, Wray LA, et al. Dissemination of evidence-base minimal psychological intervention for diabetes management in Taiwan adults with type 2 diabetes. Int J Clin Exp Med. 2016;9:14489-14498.
- 10.1002/dmrr. · doi:10.1002/dmrr
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“Evidence for a beneficial impact of telehealth on achieving treatment goals in those living with type 2 diabetes is growing (333,334).”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Crowley, M. J., Tarkington, P. E., Bosworth, H. B., Jeffreys, A. S., Coffman, C. J., Maciejewski, M. L., Steinhauser, K., Smith, V. A., Dar, M. S., Fredrickson, S. K., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.2947 · Cited by 75
Zhang, A., Wang, J., Wan, X., Zhang, Z., Zhao, S., Guo, Z., & Wang, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074173 · Cited by 50
“Although there have been published reviews of the effectiveness of telemedicine research [16,17] on diabetes, there is a lack of analysis of all the potential outcomes and the impact of telemedicine interventions on patients with type 2 diabetes.”
BackgroundRuissen, M. M., Torres-Peña, J. D., Uitbeijerse, B. S., Arenas de Larriva, A. P., Huisman, S. D., Namli, T., Salzsieder, E., Vogt, L., Ploessnig, M., van der Putte, B., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06006-2 · Cited by 43
Metadata
- Authors
- Hangaard, S., Laursen, S. H., Andersen, J. D., Kronborg, T., Vestergaard, P., Hejlesen, O., & Udsen, F. W.
- Affiliations
- Steno Diabetes Center North Jutland (DK)
- University College of Northern Denmark (DK)
- Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
- Aalborg University Hospital (DK)
- Aalborg University (DK)
- Corresponding author
- Hangaard, Stine
- ORCID
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2021-12-26
- Volume
- 17
- Issue
- 3
- Pages
- 794-825
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC10210100
- OpenAlex
- W4200263680
- Cited by
- 55
- References
- 294
- Citations by year
- 2026: 15 · 2025: 9 · 2024: 16 · 2023: 6 · 2022: 9
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Aalborg Universitet
- Novo Nordisk Fonden (NNF17SA0031404-1)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Telemedicine and Telehealth Implementation
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- telemedicine, type 2 diabetes, HbA1c, glycemic control, remote patient monitoring, diabetes management
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Telemedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effectiveness of Telemedicine Solutions for the Management of Type 2 Diabetes: A Systematic Review, Meta-Analysis, and Meta-Regression. https://app.cochat.ai/papers/10.1177/19322968211064633
- The paper
- Hangaard, S., Laursen, S. H., Andersen, J. D., Kronborg, T., Vestergaard, P., Hejlesen, O., & Udsen, F. W. (2023). The Effectiveness of Telemedicine Solutions for the Management of Type 2 Diabetes: A Systematic Review, Meta-Analysis, and Meta-Regression. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968211064633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.